Literature DB >> 1471867

Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity.

A R Bicknese1, W May, W F Hickey, W E Dodson.   

Abstract

Four unrelated children were thought to have valproate-associated hepatotoxicity. They presented with recurrent partial secondarily generalized status epilepticus and epilepsia partialis continua followed by mental and motor regression. Despite treatment with multiple antiepileptic medications, they continued to have seizures. After initiation of valproic acid (VPA), all 4 manifested liver failure within 3 months. Two of these children each had 1 sibling who was not exposed to VPA, but who developed the same clinical picture including liver failure. At the time of autopsy, all 6 children had similar neuropathological findings with focal areas of spongiosis and neuronal loss, diffuse gliosis, and Alzheimer type II cells. One VPA-treated patient underwent a successful liver transplantation only to die from relentlessly progressive neurological deterioration. We propose that many of the reported patients with VPA-associated hepatotoxicity represent undiagnosed patients with early childhood hepatocerebral degeneration, the Huttenlocher variant of Alpers' syndrome. This disease manifests by obstinate partial seizures, recurrent partial secondarily generalized status epilepticus, epilepsia partialis continua, psychomotor deterioration, and hepatic dysfunction that is exacerbated by VPA administration. The accelerated demise from liver failure in the nontransplanted patients before the central nervous system pathology fully evolves makes the diagnosis of this rare condition difficult. The occurrence of disease in the unexposed siblings suggests recessive inheritance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1471867     DOI: 10.1002/ana.410320610

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  13 in total

Review 1.  Who needs a liver transplant? (new disease specific indications).

Authors:  A Baker; A Dhawan; N Heaton
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

2.  Complete Deletion of a POLG1 Allele in a Patient with Alpers Syndrome.

Authors:  Karin Naess; Michela Barbaro; Helene Bruhn; Rolf Wibom; Inger Nennesmo; Ulrika von Döbeln; Nils-Göran Larsson; Antal Nemeth; Nicole Lesko
Journal:  JIMD Rep       Date:  2011-10-20

Review 3.  Alpers-Huttenlocher syndrome.

Authors:  Russell P Saneto; Bruce H Cohen; William C Copeland; Robert K Naviaux
Journal:  Pediatr Neurol       Date:  2013-03       Impact factor: 3.372

Review 4.  Clinical and molecular features of POLG-related mitochondrial disease.

Authors:  Jeffrey D Stumpf; Russell P Saneto; William C Copeland
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-04-01       Impact factor: 10.005

5.  Valproyl-CoA inhibits the activity of ATP- and GTP-dependent succinate:CoA ligases.

Authors:  Paula B M Luís; Jos Ruiter; Lodewijk IJlst; Isabel Tavares de Almeida; Marinus Duran; Ronald J A Wanders; Margarida F B Silva
Journal:  J Inherit Metab Dis       Date:  2013-10-24       Impact factor: 4.982

Review 6.  Valproate-induced hyperammonemic encephalopathy.

Authors:  Alberto Verrotti; Daniela Trotta; Guido Morgese; Francesco Chiarelli
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

7.  POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.

Authors:  Russell P Saneto; Inn-Chi Lee; Mary Kay Koenig; Xinhua Bao; Shao-Wen Weng; Robert K Naviaux; Lee-Jun C Wong
Journal:  Seizure       Date:  2010-02-06       Impact factor: 3.184

Review 8.  Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options.

Authors:  Ayman W El-Hattab; Fernando Scaglia
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 9.  Gastrointestinal and hepatic manifestations of mitochondrial disorders.

Authors:  Shamima Rahman
Journal:  J Inherit Metab Dis       Date:  2013-05-15       Impact factor: 4.982

Review 10.  Mitochondrial disease in childhood: nuclear encoded.

Authors:  Amy C Goldstein; Poonam Bhatia; Jodie M Vento
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.